Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

Published on 20 Feb 19, under Press releases

Cambridge, UK, and Shanghai, China, February 20 2019: Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation.

Recognizing the escalating incidence of lung cancer in China, Owlstone Medical and Renji Hospital have a mutual interest in developing and making accessible diagnostics for the early detection of disease, which can result in the reduction of health care costs to patients and providers, and an overall increase in survival rates. The two parties have therefore agreed to jointly conduct a first of its kind clinical trial in China into the early detection of lung cancer, to be led by Professor Li-wei Wang, Director of Oncology at Renji Hospital.

In conjunction, a Breath Biopsy® laboratory will be established to support the study. Renji Hospital will provide operational support for the study, and Owlstone Medical will provide its Breath Biopsy® technology, including breath collection stations, analytical instrumentation, and the procedures and training necessary to support the lab’s operation. Beyond this study, the lab will support additional research investigations in cancer and other areas.

Dr Li-wei Wang, Director of Oncology, Renji Hospital said: “Healthcare systems around the world are increasingly recognizing that better and more reliable approaches to the early detection of disease is one of the most effective ways to support patients and to control healthcare costs. Breath-based diagnostics have the potential to revolutionize the way that this challenge is approached and we are very pleased to be partnering with Owlstone Medical to establish the first Breath Biopsy lab outside of the UK. We are hopeful that our collaboration will result in screening tools that meaningfully help combat lung cancer and other diseases in China and globally.”

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “Expansion into China through the establishment of an in-country Breath Biopsy lab and formation of high value partnerships is an important part of Owlstone Medical’s strategy, significantly as access to the large healthcare networks present has the potential to substantially accelerate clinical trials. Renji Hospital is a leader in cancer and other areas of medical research and represents an ideal partner for us. Through its affiliation with the Shanghai Jiaotong University School of Medicine, and with over 50,000 inpatients per year, the studies undertaken in this newly established Breath Biopsy lab will prove to be a significant driver of our goal to save 100,000 lives, and we are excited to begin.”

ENDS

Owlstone Medical 与上海交通大学医学院附属仁济医院
率先在中国进行肺癌呼吸活检临床测试

【2019年2月20日,英国剑桥和中国上海同步发布】Owlstone Medical 有限公司是全球医疗诊断公司,开发用于早期疾病检测和精准医学应用的呼气活检器。 Owlstone Medical 与上海交通大学医学院附属仁济医院(下称仁济医院),今日宣布在中国
联合开展肺癌早期检测的临床试验,项目获得李嘉诚基金会的支持。

有见肺癌在中国的病发率不断上升,Owlstone Medical与仁济医院双方致力研发早期和广泛性的疾病检测,以降低患者的成本和医疗系统的资源,更整体提高病人的存活率。由仁济医院肿瘤科主任王理伟医生的带领下,双方合作在中国进行首次的早期肺癌呼吸活检临床测试。

与此同时,该项目计划开设呼吸活检(Breath Biopsy ®)实验室以支持研究。仁济医院将负责此研究项目的运作,Owlstone Medical将提供其呼吸活检技术(Breath Biopsy ®),包括呼吸样本收集站、分析仪器,并提供实验室高效运作所需的程序和培训。除外,实验室将支持癌症和其他领域的调研。

仁济医院肿瘤科主任王理伟医生表示:「世界各地的医疗保健系统愈来愈意识到,早期且可靠的疾病检测,是支持患者和控制医疗成本的最有效方法之一,呼吸活检是其中具潜力解决此难题的方法。我们很高兴能与Owlstone Medical合作,在英国以外建立第一个呼吸活检实验室。我们希望我们的合作将能有助发展出检测工具,有效地在中国和世界各地帮助对抗肺癌和其他疾病。」

Owlstone Medical联合创办人兼行政总裁Billy Boyle表示:「中国是Owlstone Medical业务发展的重要部分,当中的大型医疗保健网络,可大大加快临床试验的速度。仁济医院是癌症和其他医学研究领域的先驱,是我们理想的合作伙伴。通过与上海交通大学医学院合作,及每年超过50,000名住院病人,在这个新成立的呼吸活检实验室进行的研究,将成为我们拯救10万条生命的目标之助力,我们很高兴能够在此出发。」

Notes to Editors

Owlstone Medical signs partnership with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

The memorandum of understanding between Owlstone Medical and Renji Hosptial was signed in Shanghai on 18th February 2019.

For a high resolution image please contact sarah.jeffery@zymecommunications.com

Media contact

For more information please contact:

Owlstone Medical
Chris Claxton, Head of Investor Relations
chris.claxton@owlstone.co.uk

Media relations:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730919

Renji Hospital:
Dr. Yue Ma
aoyungogo84@126.com
+86 13761734987

About Renji Hospital

https://www.renji.com/

Renji Hospital, founded in 1844, is the first hospital practicing western medicine in Shanghai. With four campuses respectively in Eastern, Western, Northern and Southern Shanghai and the Shanghai Cancer Institute, Renji Hospital is a municipal hospital with a comprehensive list of medical and surgical disciplines, devoted to patient care, medical education and scientific research. In October 2010, Shanghai Cancer Institute, consists of State Key Laboratory of Oncogenes & Related Genes, Cancer Epidemiology Laboratory, 11 related research groups, public service platform of auxiliary department and magazine of Oncology merged with Renji Hospital.

All together, there are currently 2,250 authorized beds in four campuses and 55 clinical departments: Department of Gastroenterology, Cardiology, Neurosurgery, Rheumatology, Nuclear Medicine, Obstetrics and Gynecology, Gynecology Oncology, Urology, Nephrology, Anesthesiology, Pain Management, Critical Care Medicine, Radiology, Gastrointestinal Surgery, Liver Surgery, Biliary and Pancreatic Surgery, Breast Surgery, Vascular Surgery, Head and Neck Surgery, Hematology, Geriatrics, Ultrasound, Neurology, Endocrinology, Orthopedics, Orthopedics-Spine Surgery, Orthopedics- Bone & Joint Surgery, Orthopedics-bone trauma, Respiratory, Otorhinolaryngology, Orthopedics, Ophthalmology, Reproductive Medicine, Radiology, Pharmacy, Health Care, Blood Transfusion, Clinical Laboratory, Pediatrics, Rehabilitation, Stomatology, Dermatology, Oncology, Emergency Department, Thoracic Surgery, Cardiovascular Surgery, Pathology, Traditional Chinese Medicine, Clinical Nutrition, Internal Medicine Clinic, Infectious Diseases, Tumor Interventional Section, Functional Neurology, Allergy Division and Psychology.

In recent years, the number of scientific research projects has been growing year on year, including the State 973 Program, 863 Program and Key National Natural Science Foundation projects, etc. The hospital was laureated many national awards such as National Science and Technology Awards, Chinese Medical Association Awards of Science and Technology, etc. The hospital has also established partnership with medical schools and hospitals in Canada, US, France, Belgium, UK, Australia and etc.

关于上海交通大学医学院附属仁济医院

https://www.renji.com/
仁济医院建于1844年,是上海开埠后第一所西医医院。医院目前由东西南北四个院区和上海市肿瘤研究所组成,是一个学科门类齐全,集医疗、教学、科研于一体的综合性三级甲等医院:肿瘤所由癌基因与相关基因国家重点实验室、肿瘤流行病学研究室、十三个相关的研究课题组、辅助部门公共服务平台与《肿瘤》杂志编辑部组成,于2010年10月与仁济医院正式“院所合一”。目前总核定床位1650张,设有50个临床医技科室:消化科、心内科、血液科、风湿病科、老年病科、呼吸科、肾脏科、神经内科、内分泌科、肿瘤科、肿瘤介入科、康复科、急诊科、核医学科、放射诊疗科、泌尿科、胃肠外科、胆胰外科、乳腺外科、骨科、心血管外科、胸外科、血管外科、神经外科、功能神经科、肝脏外科、整形外科、麻醉科、中医科、儿科、眼科、妇产科、妇科肿瘤科、生殖医学科、五官科、头颈外科、皮肤科、感染科、口腔科、营养科、放射科、超声医学科、病理科、检验科、药剂科、输血科、内科门诊、健康保健中心、变态反应科、重症医学科。

近年来,医院申请到的科研项目及专利逐年递增,包括国家级的973计划、863计划、国家自然基金(重大、重点)项目等。医院还获得多项国家科技进步奖、中华医学科技奖、高等学校科技进步奖等。医院与美国、加拿大、法国、比利时、德国等近十个国家的二十多所医学院校建立了学术交流和友好合作关系。

Breath Biopsy®

If you want to learn more about Owlstone Medical's Breath Biopsy platform, why not download our free ebook: Breath Biopsy: The Complete Guide?

Breath Biopsy Complete Guide

Breath Biopsy Services with our world class team and facilities

View our services